Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Tables)

v2.4.0.6
SUBSEQUENT EVENTS (Tables)
 6 Months Ended
Mar. 31, 2013
Subsequent Events Tables  
Schedule of Pro Forma Balance Sheet to reflect subsequent warrant exercises

The Pro-forma Balance Sheet as of March 31, 2013 is presented to reflect the Series B warrant exercises:

 

Proforma Balance Sheet

 

   
   

March 31, 2013

     Adjustments    

Proforma March 31, 2013

  
ASSETS              
               
CURRENT ASSETS              
Cash   $ 1,765,208     $ 5,056,337     $ 6,821,545  
Prepaid expenses     208,838               208,838  
                         
Total Current Assets     1,974,046               7,030,383  
                         
EQUIPMENT, net     38,383               38,383  
                         
OTHER ASSETS                        
                         
Patent costs, net     584,866               584,866  
                         
TOTAL ASSETS   $ 2,597,295             $ 7,653,632  
                         
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                        
                         
CURRENT LIABILITIES                        
Accounts payable and accrued expenses   $ 314,293             $ 314,293  
Notes payable     3,643               3,643  
                         
Total Current Liabilities     317,936               317,936  
                         
TOTAL LIABILITIES     317,936               317,936  
                         
STOCKHOLDERS' EQUITY (DEFICIT)                        
Preferred stock, Series B     544               544  
Common stock     4,970       424       5,394  
Additional paid-in capital     33,314,851       5,055,913       38,370,764  
Accumulated deficit     (21,628,748 )             (21,628,748 )
Deficit accumulated during the development stage     (9,412,258 )             (9,412,258 )
                         
Total Stockholders' Equity (Deficit)     2,279,359               7,335,696  

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

   $ 2,597,295             $ 7,653,632  

 

The accompanying notes are an integral part of these financial statements.